Publications by authors named "Anupa Arora"

Claim this Profile
A
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.
Leonardo Iaccarino, Samantha C Burnham, Ilke Tunali, Jian Wang, Michael Navitsky, Anupa K Arora

Neuroimage Clin· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of a F-Flortaucipir PET Visual Stratification Method.
Ilke Tunali, Jian Wang, Anupa K Arora, Min Jung Kim, Sergey Shcherbinin

J Nucl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Sergey Shcherbinin, Amanda Morris, Ixavier A Higgins, Ilke Tunali, Ming Lu, Anupa K Arora

Alzheimers Dement (N Y)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials.
Ming Lu, Michael J Pontecorvo, Michael D Devous, Anupa K Arora, Nicholas Galante

JAMA Neurol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
Adam S Fleisher, Michael J Pontecorvo, Michael D Devous, Ming Lu, Anupa K Arora

JAMA Neurol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study.
Michael J Pontecorvo, C Dirk Keene, Thomas G Beach, Thomas J Montine, Anupa K Arora

EJNMMI Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Michael J Pontecorvo, Michael D Devous, Ian Kennedy, Michael Navitsky, Ming Lu, Anupa K Arora

Brain· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and cortical decline in the aphasic variant of Alzheimer's disease.
Emily Joy Rogalski, Jaiashre Sridhar, Adam Martersteck, Benjamin Rader, Derin Cobia, Anupa K Arora

Alzheimers Dement· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Michael J Pontecorvo, Andrew Siderowf, Bruno Dubois, P Murali Doraiswamy, Giovanni B Frisoni, Anupa K Arora

Dement Geriatr Cogn Disord· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.
Michael J Pontecorvo, Anupa K Arora, Marybeth Devine, Ming Lu, Nick Galante

Eur J Nucl Med Mol Imaging· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Michael J Pontecorvo, Michael D Devous, Michael Navitsky, Ming Lu, Stephen Salloway, Anupa K Arora

Brain· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Michael Grundman, Keith A Johnson, Ming Lu, Andrew Siderowf, Grazia Dell'Agnello, Anupa K Arora

Dement Geriatr Cogn Disord· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Andrew Siderowf, Michael J Pontecorvo, Holly A Shill, Mark A Mintun, Anupa Arora

BMC Neurol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Michael Grundman, Michael J Pontecorvo, Stephen P Salloway, P Murali Doraiswamy, Adam S Fleisher, Anupa K Arora

Alzheimer Dis Assoc Disord· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Christopher M Clark, Michael J Pontecorvo, Thomas G Beach, Barry J Bedell, R Edward Coleman, Anupa Arora

Lancet Neurol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Abhinay D Joshi, Michael J Pontecorvo, Chrisopher M Clark, Alan P Carpenter, Danna L Jennings, Anupa Arora

J Nucl Med· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis